Ibrutinib (CAS 937263-43-9) -ibrutinib api

Ibrutinib (CAS 937263-43-9) is a high-purity pharmaceutical API classified as a selective BTK (Bruton’s Tyrosine Kinase) inhibitor, featuring a small-molecule heterocyclic structure with irreversible binding to the BTK active site. It selectively inhibits BTK, a key enzyme in the B-cell receptor signaling pathway, blocking the proliferation, survival, and migration of malignant B cells. This premium API exhibits excellent oral bioavailability and stable pharmacokinetics, ensuring consistent efficacy in capsule formulations with minimal off-target effects on other kinases.

It caters to the core needs of oncology drug manufacturers, biotech research institutions, and clinical suppliers. Widely applied in developing treatments for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM), it aligns with the demand for targeted B-cell malignancy therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring reliability for clinical and research use. For businesses prioritizing innovative, well-tolerated anticancer solutions, this Ibrutinib API serves as a critical raw material for advancing hematologic oncology research and therapeutic development.